Skip to main content

Health condition · Clinically reviewed

Marginal zone lymphoma, three subtypes, one indolent family.

Extranodal, splenic and nodal disease each present differently - and each has its own well-defined, often gentle treatment pathway.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against BSH, ESMO and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including hepatitis C-directed therapy, rituximab and BTK inhibitors.

Key facts

Marginal zone lymphoma at a glance.

The essentials, in plain English - what it is, the three subtypes, and how each is treated in the UK today.

  • What it is

    A group of indolent (slow-growing) B-cell non-Hodgkin lymphomas arising from marginal zone B-cells - see lymphoma.

  • Three subtypes

    Extranodal (MALT), splenic and nodal marginal zone lymphoma - each with a different presentation and evidence base.

  • Most common

    Extranodal MALT lymphoma - most often gastric and linked to H. pylori infection - see MALT lymphoma.

  • Splenic subtype

    Presents with splenomegaly and cytopenias, frequently associated with hepatitis C infection.

  • Rarest subtype

    Nodal marginal zone lymphoma - presents with painless peripheral lymphadenopathy, much like other low-grade lymphomas.

  • Key principle

    Asymptomatic disease is often watched, not treated - and treating an underlying infection can sometimes treat the lymphoma too.

Why this guide matters

A stepped plan built around subtype and cause.

Marginal zone lymphoma is rare, usually indolent, and often more treatable than the word "lymphoma" first suggests. The three points below shape everything else on this page.

  • Subtype changes everything

    Extranodal, splenic and nodal disease are managed differently - knowing which subtype you have shapes every decision that follows.

  • Underlying causes matter

    Hepatitis C in splenic disease, or H. pylori in extranodal disease, can sometimes be treated to treat the lymphoma itself.

  • Watch and wait is a valid plan

    For indolent, asymptomatic disease, active monitoring avoids unnecessary treatment without compromising long-term outcomes.

How the diagnosis is made

From first bloods to a confirmed subtype.

The steps a UK haematology-oncology team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Blood count and film

    FBC, blood film and LDH look for cytopenias, circulating lymphoma cells and disease burden.

  2. 02

    Assessing

    Biopsy and immunohistochemistry

    Lymph node, spleen or splenectomy specimen - CD20 positive, CD5 negative, cyclin D1 negative to exclude mantle cell lymphoma.

  3. 03

    Assessing

    Hepatitis C serology

    Particularly important in splenic marginal zone lymphoma - treating HCV can induce remission without chemotherapy.

  4. 04

    Confirming

    Bone marrow biopsy

    Assesses marrow involvement and completes formal disease staging.

  5. 05

    Confirming

    CT or PET-CT staging

    Maps nodal, splenic and extranodal disease extent - specialist commissioned.

  6. 06

    Deciding

    Haematology-oncology MDT

    A specialist multidisciplinary team confirms the subtype, stage and agrees the treatment pathway.

  7. 07

    Deciding

    Subtype-specific work-up

    Splenic disease is checked for hypersplenism; nodal disease is mapped by site; extranodal disease follows the MALT lymphoma pathway.

Typical timeline: initial bloods to a confirmed subtype and plan within a few weeks.

Symptoms

What marginal zone lymphoma actually looks like.

Presentation depends heavily on subtype - splenic disease causes abdominal fullness and cytopenias, nodal disease causes painless swelling, extranodal disease is site-specific.

  • Splenomegaly

    An enlarged spleen causing abdominal fullness or early satiety - the hallmark of splenic marginal zone lymphoma.

  • Fatigue

    A common, non-specific symptom, often related to anaemia or the disease itself.

  • Cytopenias

    Anaemia and thrombocytopenia from hypersplenism - bruising, breathlessness or infection can follow.

  • Painless lymphadenopathy

    Enlarged, non-tender lymph nodes - the presenting feature of nodal marginal zone lymphoma.

  • Site-specific symptoms

    Extranodal (MALT) disease causes symptoms local to its site - dyspepsia in gastric disease - see MALT lymphoma.

  • Hepatitis C association

    Splenic disease is often linked to chronic HCV infection - a detail that changes the entire treatment plan.

  • Asymptomatic, incidental disease

    Many cases are picked up on routine bloods or imaging before symptoms develop.

  • Red flag - rapid progression

    Fast-growing nodes, worsening cytopenias or new systemic symptoms need prompt specialist reassessment.

Treatment

How marginal zone lymphoma is treated in the UK.

Watch and wait for indolent disease, hepatitis C treatment first where relevant, and rituximab-based therapy stepping up as needed.

  • Watch and wait

    Appropriate for indolent, asymptomatic disease of any subtype - active monitoring without immediate treatment.

  • Hepatitis C antiviral therapy

    First-line for splenic marginal zone lymphoma with HCV infection - can induce lymphoma remission without chemotherapy.

  • Rituximab monotherapy

    For splenic disease without HCV, or progressive disease - anti-CD20 therapy, specialist commissioned - see rituximab clinic.

  • Splenectomy

    An alternative to rituximab for splenic marginal zone lymphoma without HCV - controls symptoms and hypersplenism directly.

  • Rituximab plus chemotherapy

    Bendamustine or CVP combined with rituximab for nodal or disseminated disease - specialist commissioned.

  • Localised radiotherapy

    For localised nodal disease confined to one site - specialist commissioned.

  • BTK inhibitors

    Selective for relapsed disease - a targeted oral option used under specialist supervision.

  • MDT-led specialist care

    Haematology-oncology multidisciplinary review, alongside support from Lymphoma Action.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haematologist knows your case, subtype and history and can tell you which parts apply to you. If in doubt, get seen.

  • British Society for Haematology (BSH). Guideline for the diagnosis and management of marginal zone lymphomas.

  • European Society for Medical Oncology (ESMO). Marginal zone lymphomas: clinical practice guideline.

  • Lymphoma Action. Information on marginal zone lymphoma for patients.

  • NICE. Referral guidelines and technology appraisals for non-Hodgkin lymphoma.

Red flags

When marginal zone lymphoma needs urgent attention.

Most marginal zone lymphoma follows a calm, planned pathway. These are the situations that call for prompt specialist reassessment.

  • Worsening cytopenias

    Falling haemoglobin or platelets in splenic disease can signal progressive hypersplenism or transformation - needs prompt review.

  • Rapidly enlarging nodes or spleen

    Fast growth in any subtype raises the possibility of transformation to a more aggressive lymphoma.

  • New B symptoms

    Drenching night sweats, unexplained fever or significant weight loss warrant urgent haematology assessment.

  • Untreated hepatitis C

    Unrecognised HCV in splenic disease means a potentially curative, non-chemotherapy option is being missed.

  • Bleeding or bruising

    Severe thrombocytopenia from hypersplenism can cause bleeding - needs same-day assessment.

  • Recurrent infections

    Neutropenia or immune dysfunction from marrow involvement increases infection risk and needs monitoring.

  • Suspected transformation

    A sudden change in behaviour - new pain, rapid growth or systemic illness - should prompt urgent re-biopsy.

  • Bulky or disseminated disease at diagnosis

    Extensive disease at presentation is discussed early for systemic therapy rather than watch and wait.

Living with it

A rare lymphoma, with a genuinely gentle pathway.

Four things that make the biggest difference through diagnosis and follow-up - knowing your subtype and HCV status, accepting watch and wait when appropriate, staying up to date with bloods, and trusting the outlook.

A quiet reminder

This is one of the gentler lymphomas.

A new diagnosis can feel frightening, but the stepped pathway - watching, treating a cause, or stepping up therapy only when needed - has a strong track record across all three subtypes.

  1. 01 Testing

    Know your HCV status

    For splenic disease, hepatitis C testing shapes the entire treatment pathway - ask if it has been checked.

  2. 02 Monitoring

    Watch and wait is active care

    Regular review, not treatment, is often the right choice for indolent disease - it is not neglect.

  3. 03 Follow-up

    Keep blood tests up to date

    Routine FBC tracks cytopenias and disease activity between clinic visits.

  4. 04 Outlook

    Generally indolent, often manageable

    Most marginal zone lymphoma behaves slowly, with long periods of stability between treatments.

Frequently asked

Everything we get asked about marginal zone lymphoma.

Quick answers on subtypes, hepatitis C, watch and wait, and treatment options.

  • What is marginal zone lymphoma?

    It is a group of indolent (slow-growing) B-cell non-Hodgkin lymphomas arising from marginal zone B-cells. There are three subtypes - extranodal (MALT lymphoma, the most common), splenic, and nodal marginal zone lymphoma - each with a distinct presentation.

  • What is the difference between the three subtypes?

    Extranodal marginal zone lymphoma (MALT lymphoma) most often affects the stomach and is linked to H. pylori infection. Splenic marginal zone lymphoma causes splenomegaly and cytopenias and is often associated with hepatitis C. Nodal marginal zone lymphoma, the rarest, presents with painless lymph node swelling.

  • Can hepatitis C treatment really treat a lymphoma?

    Yes, in splenic marginal zone lymphoma associated with hepatitis C. Treating the HCV infection with antiviral therapy can induce lymphoma remission without any chemotherapy - a striking example of treating the underlying cause rather than the cancer directly.

  • Why would I be offered watch and wait instead of treatment?

    Marginal zone lymphoma is typically indolent. If the disease is asymptomatic and not causing problems, active monitoring avoids unnecessary treatment side effects while achieving the same long-term outcome for many patients.

  • What treatment is used for splenic disease without hepatitis C?

    Rituximab monotherapy or splenectomy are the main options, chosen with a specialist based on symptoms, spleen size and patient preference. Both are specialist commissioned treatments.

  • How is nodal or disseminated marginal zone lymphoma treated?

    Rituximab combined with chemotherapy such as bendamustine or a CVP regimen is standard for nodal or disseminated disease. Localised nodal disease may instead be treated with radiotherapy, and BTK inhibitors are an option for relapsed disease.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.